<DOC>
	<DOCNO>NCT00309166</DOCNO>
	<brief_summary>The main aim vaccine prevent cervical cancer woman . However , could also relevant vaccinate select group male . Therefore , study design evaluate safety immunogenicity HPV vaccine pre-teen adolescent male subject age 10-18 year .</brief_summary>
	<brief_title>Evaluation Immunogenicity Safety GlaxoSmithKline Biologicals ' HPV Vaccine Young Males .</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion criterion : A male , include , 10 18 year age time first vaccination . Written inform consent obtain subject prior enrolment For subject legal age consent , write informed consent must obtain subject 's parent/guardian . In addition , write informed assent must obtain subject . Healthy subject establish medical history clinical examination enter study . Free obvious health problem establish medical history clinical examination enter study . Exclusion criterion : Previous vaccination Human Papillomavirus ( HPV ) . Previous vaccination Hepatitis B , know clinical history Hepatitis B infection . Cancer autoimmune disease treatment .</criteria>
	<gender>Male</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>